Literature DB >> 31841177

LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1.

D-Z Chen1, T-F Wang, W-C Dai, X Xu, P-F Chen.   

Abstract

OBJECTIVE: To uncover the role of FOXD2-AS1 in aggravating the progression of cervical cancer (CC) by negatively regulating caudal-related homeobox 1 (CDX1).
MATERIALS AND METHODS: FOXD2-AS1 levels in CC tissues with different tumor sizes and tumor staging were detected. Meanwhile, FOXD2-AS1 levels in CC patients either with vascular invasion, lymphatic metastasis or not were detected. Survival analysis on CC patients expressing high level or low level of FOXD2-AS1 was conducted by introducing the Kaplan-Meier method. After the silence of FOXD2-AS1, proliferative changes in SiHa and HeLa cells were assessed through cell counting kit-8 (CCK-8) and 5-Ethynyl-2'-deoxyuridine (EdU) assay. Subcellular distribution of FOXD2-AS1 in CC cells was analyzed. Next, CDX1 level in CC tissues and para-tumor tissues was determined. The potential correlation between CDX1 level and FOXD2-AS1 level was evaluated by the linear regression analysis. At last, the regulatory effects of FOXD2-AS1/CDX1 on the proliferative ability of CC were examined.
RESULTS: FOXD2-AS1 was upregulated in CC tissues relative to those of para-tumor tissues, especially in those with larger tumor size and advanced tumor staging. Its level was not correlated to vascular invasion and lymphatic metastasis of CC. CC patients expressing a high level of FOXD2-AS1 suffered worse prognosis than those with low level. The silence of FOXD2-AS1 attenuated SiHa and HeLa cells to proliferate. FOXD2-AS1 was found to be mainly enriched in the nucleus. CDX1 was downregulated in CC tissues and its level was negatively regulated by FOXD2-AS1. The silence of CDX1 could reverse the regulatory effect of FOXD2-AS1 on the proliferative ability of CC cells.
CONCLUSIONS: FOXD2-AS1 is upregulated in CC and its high level predicts a poor prognosis of CC patients. It accelerates the malignant progression of CC via negatively regulating CDX1 level.

Entities:  

Year:  2019        PMID: 31841177     DOI: 10.26355/eurrev_201912_19660

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  FOXD2-AS1 acts an oncogene in esophageal squamous cell carcinoma through sponging miR-204-3p.

Authors:  Dongbo Luo; Adili Salai; Hongbo Lv; Yang Wang; Yunfei Gao
Journal:  Clin Transl Oncol       Date:  2022-07-01       Impact factor: 3.340

2.  LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.

Authors:  Zhihai Li; Qiaozhi Jin; Yana Sun
Journal:  J Clin Lab Anal       Date:  2022-05-19       Impact factor: 3.124

Review 3.  The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles.

Authors:  Yongping Zhang; Chaojie Liang; Yu Zhang; Zhinmin Wang; Ruihuan Li; Zhigang Wei; Jiansheng Guo
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

4.  Identification and in vitro validation of prognostic lncRNA signature in head and neck squamous cell carcinoma.

Authors:  Jian Wang; Qinjiang Bian; Jialin Liu; Adili Moming
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.